Your browser doesn't support javascript.
loading
Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients.
Wang, Zhan; Chen, Juan; Zhong, Mei-Zuo; Huang, Juan; Hu, Yuan-Ping; Feng, De-Yun; Zhou, Zhi-Jiao; Luo, Xiao; Liu, Zhao-Qian; Jiang, Wu-Zhong; Zhou, Wei-Bing.
Affiliation
  • Wang Z; Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
  • Chen J; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
  • Zhong MZ; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, 410078, People's Republic of China.
  • Huang J; Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
  • Hu YP; Hunan Province Clinic Meditech Research Center for Breast Cancer, Changsha, 410008, People's Republic of China.
  • Feng DY; Hunan Province Clinic Meditech Research Center for Breast Cancer, Changsha, 410008, People's Republic of China.
  • Zhou ZJ; Department of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
  • Luo X; Department of Pathology, The third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China.
  • Liu ZQ; Department of Pain, The third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China.
  • Jiang WZ; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
  • Zhou WB; Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, 410078, People's Republic of China.
Cancer Chemother Pharmacol ; 79(3): 535-543, 2017 03.
Article in En | MEDLINE | ID: mdl-28243684
ABSTRACT

PURPOSE:

To investigate the associations of ANLN expression with prognosis of breast cancer and clinical outcome of anthracycline-based chemotherapy.

METHODS:

This study enrolled 308 breast cancer patients in which 264 of them received anthracycline-based chemotherapy. Immunohistochemistry was used to detect ANLN expression level of the patients. Clinical characteristics of the patients were collected, and associations of ANLN expression with prognosis were analyzed.

RESULTS:

Our results showed that ANLN expression was associated with survival of breast cancer patients, and it was also related to clinical outcome of patients received anthracycline-based chemotherapy. Breast cancer patients with high expression of ANLN would have poor prognosis and poor clinical outcome to anthracycline-based chemotherapy.

CONCLUSION:

ANLN could be an independent prognosis predictor for breast cancer, and its expression might be used to predict the anthracycline-based chemotherapy clinical outcome in breast cancer patients.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Anthracyclines / Microfilament Proteins / Antibiotics, Antineoplastic Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 2017 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Anthracyclines / Microfilament Proteins / Antibiotics, Antineoplastic Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 2017 Document type: Article